Travapress Rompharm eye drops solution 0.04 mg/ml bottle 2.5 ml

The drug "Travapress Rompharm" is used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Composition

The active substance is travoprost (1 ml of solution contains 0.04 mg of travoprost).

Excipients: polyquad, boric acid, sodium chloride, mannitol (E 421), polyethylene glycol (macrogol) glyceryl hydroxystearate, propylene glycol, sodium hydroxide 1 M or hydrochloric acid 1 M, purified water.

Contraindication

Hypersensitivity to the active substance or other components of the drug.

Method of application

For ophthalmic use.

Use in adults, including elderly patients

One drop of Travapress Rompharm into the conjunctival sac(s) of the affected eye(s) once daily. The optimal effect is achieved when the dose is administered in the evening.

After instillation, it is recommended to pinch the nasolacrimal duct or slightly close the eyelids. This reduces the systemic absorption of drugs administered into the eye, which may reduce the likelihood of systemic side effects.

If more than one topical ophthalmic agent is used, the interval between their applications should be at least 5 minutes.

If a dose is missed, treatment should be continued with the next scheduled dose. The dose should not exceed one drop in the affected eye(s) once daily.

If another ophthalmic antiglaucoma drug is replaced with Travapress Rompharm, the use of the other drug should be discontinued and the use of Travapress Rompharm should be started the next day.

Application features

Pregnant women

Travoprost should not be used in women of reproductive age not using contraceptives.

Travoprost has harmful pharmacological effects on pregnant women and on the fetus/newborn child. Travoprost should not be used during pregnancy unless clearly necessary.

It is not known whether travoprost from eye drops passes into breast milk. It is not recommended to use travoprost during breastfeeding.

Children

The efficacy and safety of travoprost in patients under 18 years of age have not been established, therefore its use in this group of patients is not recommended until relevant data are obtained.

Drivers

Travoprost has no or negligible influence on the ability to drive or use machines, however, as with any eye drops, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs during instillation, the patient should wait until the vision clears before driving or using machines.

Overdose

There have been no reports of overdose. Local overdose is unlikely to cause or be associated with toxic effects. In case of local overdose, the eye(s) should be flushed with warm water. In case of accidental ingestion, symptomatic and supportive therapy should be administered.

Side effects

The most common adverse reactions observed during travoprost studies were ocular hyperemia and iris hyperpigmentation, which occurred in approximately 20% and 6% of patients, respectively.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C, out of the reach of children.

Shelf life - 3 years.

The shelf life of the drug after opening the bottle is 28 days.